KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.

Nat Med · 2025-Oct · PMID 40750932

Panel A提取完成待 EXE 对齐验证

Overall survival

Extended Data Fig. 6. Kaplan-Meier estimates of survival by SETD2 mutational status. a , Overall survival. b , Progression-free survival. HR was estimated using the Cox proportional hazards model, with adjustment for IMDC risk category. HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; OS, overall survival; PFS, progression-free survival; SETD2 , SET domain containing 2, histone lysine methyltransferase gene; WT, wild type.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-18T19:53:19+00:00